Clinical trial · Observational
Prospective Hyperthermia Database in Cancer Patients (HT Register)
Prospektive Hyperthermie-Datenbank Bei Krebspatienten (HTRegister)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This monocentric study registry records all cancer patients at the Charité which are treated with hyperthermia to examine the therapeutic use of hyperthermia in cancer patients in the general application and to obtain an accurate risk-benefit balance After confinement in this database are the patients prospectively in order to complications, disease status and survival status tracked. Furthermore there is the possibility in the course of this study to an optional take part in translational accompanying research with the aim of prognostic factors for response to hyperthermia treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Hyperthermia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperthermie Register | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hyperthermie Register
- description
- Hyperthermia simultaneous with Radiotherapy alone, Hyperthermia simultaneous with Chemotherapy alone, Hyperthermia simultaneous with Radiochemotherapy alone
- interventionNames
- Other: Hyperthermie Register
Primary outcomes (2)
- measure
- Effectivity
- timeFrame
- Through the study completion, up to 10 years
- description
- To determine the effectiveness of hyperthermia treatment, patients are tracked in terms of overall survival , progression-free survival and disease-free survival
- measure
- Toxicity
- timeFrame
- Through the study completion, up to 10 years
- description
- Toxicity assessment based on Common Toxicity Criteria Scoring
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Contrazeption with female patients at the capable of bearing children age * Written agreement is present (DvH, ICH-GCP) * Patients, who participate at the same time in a interventional study, can nevertheless in this register study participate if this none Exclusion criterion for the interventional study represents. * With children must the treatment with one of the GPOH agreed Pattern take place Exclusion Criteria: * Exclusion criteria for the hyperthermia (such as hip prosthesis in the therapeutic area, metal implants/marker, patients with cardiac pacemakers) * mental disease, what the proper study participation does not allow.
References
Publications (0)
Data not yet available